US FDA approved new drug Duzallo that is fixed dose combination of two active pharmaceutical ingredients namely lesinurad and allopurinol for the treatment of elevated uric acid level (hyperuricemia) associated with gout who are not responding to daily dose of allopurinol alone. This is the first drug approved by US FDA that contains such combination for the treatment of gout. However, Duzallo is not recommended for the treatment of asymptomatic hyperuricemia.
Gout is an inflammatory disease associated with elevated levels of uric acid in the blood that deposits in the form of crystals around joints and bones and causes intense pain. Affected joints become tender, red, hot and inflamed. Most commonly affected areas are toes, hands, knees etc. The exact cause of elevation of uric acid is unknown but many researchers believe that genetic predisposition and dietary factors play important role in the pathophysiology of gout. It is common disease that usually affects people in middle or later ages. Historically, it is known as disease of kings or rich man's disease.
Incidence of disease can be minimized by changing your life style e.g doing regular exercise, eating food that does not produce uric acid as a by product in the body, avoid smoking and alcohol consumption, control over obesity and consuming vitamin C through natural origin.
Duzallo contains two active pharmaceutical ingredients e.g lesinurad that inhibits uric acid readsorption and allopurinol that is xanthine oxidase inhibitor. So, Duzallo works by increasing excretion and inhibiting production of uric acid. Duzallo provides better control over uric acid in those people who are not responding to allopurinol alone.
Duzallo Side effects
According to health authorities following side effects can expected during therapy depending upon patient overall health, age and genetic predispositions.
- Renal Impairment
- Hypersensitivity reactions
- Cardiovascular events
- Bone Marrow suppression
- Increased level of creatinine
- Gastro-esophageal reflux disease
- Abdominal Discomfort
Duzallo Uses/Patient Information
US FDA approved Duzallo for the treatment of elevated uric acid level (hyperuricemia) associated with gout who are not responding to daily dose of allopurinol alone. Duzallo is not recommended for the treatment of asymptomatic hyperuricemia.
Dozallo will be available for oral administration in the form of tablets. However, standard dosage frequency of Duzallo is 1 tablet per day that contains 200mg lesinurad and 300mg allopurinol. However, dose adjustment should be kept under consideration in case of toxicity or renal impairment.